Ricardo N. Ramirez, PhD, is a genomic scientist and data science leader with deep expertise in epigenetics, computational biology, immunology, and gene editing technologies. He earned his PhD at the University of California, Irvine, where he integrated epigenomic profiling and computational modeling to map gene regulatory networks underlying human myeloid differentiation, contributing to both the ENCODE and STATegra consortia.

He then completed a postdoctoral fellowship at Harvard Medical School, shifting his focus to adaptive immunity. There, he investigated regulatory T cells and the transcription factor FoxP3, uncovering how 3D chromatin architecture shapes lineage-specific gene expression, and served as an active member of the ImmGen consortium.

Ricardo later joined a Boston-based biotech startup as a Data Science lead, directing genomic specificity and safety assessments for next-generation epigenetic medicines advancing toward the clinic.

He is now the founder of a data science consulting practice, partnering with biotech companies and non-profit foundations to drive drug discovery efforts, computational modeling, and the analysis of complex multi-omic datasets.

As Chief Scientific Officer for the MED13L Foundation, Ricardo leads investigational research and preclinical strategy to advance viable therapies for those affected by MED13L syndrome. With a deep value to providing effective leadership, he is equally committed to serving families—bridging science, lived experience, and advocacy to unite researchers, clinicians, and caregivers. By centering family voices alongside scientific rigor, Ricardo helps ensure that research efforts remain aligned with real-world needs and focused on delivering meaningful impact for the MED13L community.

Organizations
-Scientific Advisory Board Member for NeuCyte Inc.
-Medical Advisory Board Member for Koolen-de Vries Foundation.

RNR Consulting LLC clients
-Ionis Pharmaceuticals Inc, NeuCyte Inc, CombinedBRAIN